Jazz Pharmaceuticals Plc (JAZZ)
214.00
-0.65
(-0.30%)
USD |
NASDAQ |
Oct 23, 16:00
213.02
-0.98
(-0.46%)
After-Hours: 20:00
Jazz Pharmaceuticals Enterprise Value : 16.08B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 16.08B |
| October 22, 2026 | 16.12B |
| October 21, 2026 | 15.95B |
| October 20, 2026 | 16.06B |
| October 19, 2026 | 15.72B |
| October 16, 2026 | 15.83B |
| October 15, 2026 | 16.10B |
| October 14, 2026 | 15.79B |
| October 13, 2026 | 15.84B |
| October 12, 2026 | 16.25B |
| October 09, 2026 | 16.36B |
| October 08, 2026 | 16.62B |
| October 07, 2026 | 17.19B |
| October 06, 2026 | 17.20B |
| October 05, 2026 | 17.50B |
| October 02, 2026 | 17.48B |
| October 01, 2026 | 17.31B |
| September 30, 2026 | 17.21B |
| September 29, 2026 | 17.27B |
| September 28, 2026 | 17.65B |
| September 25, 2026 | 17.63B |
| September 24, 2026 | 17.52B |
| September 23, 2026 | 17.43B |
| September 22, 2026 | 17.80B |
| September 21, 2026 | 17.86B |
| Date | Value |
|---|---|
| September 18, 2026 | 17.81B |
| September 17, 2026 | 18.01B |
| September 16, 2026 | 17.99B |
| September 15, 2026 | 17.82B |
| September 14, 2026 | 18.14B |
| September 11, 2026 | 18.14B |
| September 10, 2026 | 17.79B |
| September 09, 2026 | 17.85B |
| September 08, 2026 | 17.77B |
| September 04, 2026 | 18.20B |
| September 03, 2026 | 18.25B |
| September 02, 2026 | 18.12B |
| September 01, 2026 | 18.00B |
| August 31, 2026 | 18.45B |
| August 28, 2026 | 18.06B |
| August 27, 2026 | 18.48B |
| August 26, 2026 | 18.36B |
| August 25, 2026 | 19.07B |
| August 24, 2026 | 18.70B |
| August 21, 2026 | 18.69B |
| August 20, 2026 | 18.33B |
| August 19, 2026 | 18.55B |
| August 18, 2026 | 18.61B |
| August 17, 2026 | 18.30B |
| August 14, 2026 | 18.08B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Avadel Pharmaceuticals Plc | -- |
| GH Research Plc | 878.08M |
| Cosmo NV | -- |
| Corcept Therapeutics, Inc. | 8.967B |
| Eli Lilly & Co. | 1.245T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 192.80M |
| Revenue (Quarterly) | 1.208B |
| Total Expenses (Quarterly) | 1.016B |
| EPS Diluted (Quarterly) | 2.778 |
| Gross Profit Margin (Quarterly) | 76.30% |
| Profit Margin (Quarterly) | 15.96% |
| Earnings Yield | 6.78% |
| Operating Earnings Yield | 6.85% |
| Normalized Earnings Yield | 7.786 |